Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.

Biomolecules - 26 Jan 2021

Malik Vidhi, Kumar Vipul, Kaul Sunil C, Wadhwa Renu, Sundar Durai

Abstract excerpt

The anticancer activities of Withaferin-A (Wi-A) and Withanone (Wi-N) from Ashwagandha and Caffeic Acid Phenethyl Ester (CAPE) from honeybee propolis have been well documented. Here, we examined the binding potential of these natural compounds to inhibit the constitutive phosphorylation of epidermal growth factor receptors (EGFRs). Exon 20 insertion mutants of EGFR, which show resistance to various FDA approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Computer Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dimerization

Share to Erlotinib Hydrochloride

Share to Ligands

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 33530424
DOI: 10.3390/biom11020160
PMCID: PMC7911128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.PMID 33530424Read ↗

Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2.Semantic proximity Read ↗

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Semantic proximity Read ↗

Towards identification of novel inhibitors of EGFR mutants through in-silico approach.Semantic proximity Read ↗

Identification of Gallagyldilacton as a Mutation-Biased EGFR Inhibitor from Punica granatum Peel via Integrative Computational AnalysisSemantic proximity Read ↗

Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Semantic proximity Read ↗

Orthoallosteric EGFR-TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation.Semantic proximity Read ↗

Proposing New Potential Candidates to Inhibit EGFR via Machine Learning AlgorithmSemantic proximity Read ↗

Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors.Semantic proximity Read ↗

Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase.Semantic proximity Read ↗

Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin ASemantic proximity Read ↗

Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites.Semantic proximity Read ↗

Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.